Oct, 26, 2015
Fellowship recognizes Stegemann’s patient-centric research to simplify medication management and improve patient outcomes
Morristown, N.J., October 26, 2015 – Sven Stegemann, Ph.D., a member of Capsugel’s Pharmaceutical Business Development team and an endowed professor for patient-centric drug development and manufacturing at Graz University of Technology in Austria, was elected as a 2015 Fellow by the American Association of Pharmaceutical Scientists (AAPS) during the Opening Session of the 2015 AAPS Annual Meeting and Exposition in Orlando, Fla. Stegemann, an 18-year veteran of the company, was also recognized with the 2015 AAPS Manufacturing and Engineering (MSE) Section Service Award and the 2015 Most Outstanding Manuscript Award in AAPS PharmSciTech during the Annual Meeting.
AAPS Fellow status is awarded to select AAPS members who have shown professional excellence in the fields relevant to the mission of AAPS, sustaining a level of superior and distinguished professional contributions in a relevant field. Stegemann’s research has focused on how patients use and administer medicines developed by the pharmaceutical industry. His findings have informed efforts to simplify medication management and ensure the delivery of medicines in more convenient, patient-centric forms, improving health outcomes while allowing patients to maintain independence.
“Receiving these awards is a unique honor for which I am very thankful to AAPS,” said Stegemann. ”I am especially grateful for the AAPS Fellowship Award given its prestige but, more importantly, for the implicit support it provides to the patients we are serving through the development and manufacturing of patient-centric medicines.”
In addition to receiving Fellowship status, the AAPS MSE section chose Stegemann as a recipient of the 2015 MSE Section Service Award to recognize his contributions to the MSE section as an extraordinary volunteer.
The manuscript authored by Stegemann et al, titled Application on QbD Principles for the Evaluation of Empty Hard Capsules as an Input Parameter in Formulation Development and Manufacturing, was awarded 2015 Most Outstanding Manuscript Award in AAPS PharmSciTech. The study, which examined the Critical Quality Attributes within and between different batches of empty hard capsules to better understand their variabilities and impact on the desired quality and performance of the final dosage form, provided the first comprehensive collection of relevant Quality by Design (QbD) data for hard capsules. The study confirmed that Capsugel capsules are suitable excipients for QbD-based product development and manufacturing. The manuscript was co-authored with Paul Connolly, Wayne Matthews, Rodger Barnett, Mike Aylott, Karin Schrooten, Dominique Cadé, Anthony Taylor, and Massimo Bresciani.
“Dr. Stegemann’s patient-centric research has fueled several innovations that will make medicines easier to take and improve treatment outcomes,” said Keith Hutchison, Senior Vice President, Research and Development, Capsugel. “We are proud that Dr. Stegemann has been recognized for his important work through his election as an 2015 AAPS Fellow.”
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit www.capsugel.com.